Vipin K. Garg is the CEO of Altimmune, a company he joined in late 2018. With over 30 years in biotech, he knows how to grow companies. He earned his Ph.D. in Biochemistry from the University of Adelaide, which shows...

Vipin K. Garg is the CEO of Altimmune, a company he joined in late 2018. With over 30 years in biotech, he knows how to grow companies. He earned his Ph.D. in Biochemistry from the University of Adelaide, which shows his strong background in science. Before Altimmune, he was the CEO of Neos Therapeutics, where he helped launch major medications for ADHD. Garg also led Tranzyme Pharma and held key roles in other biotech firms including Apex Bioscience and DNX Bio-Therapeutics. This mix of experience has given him a deep understanding of how to develop and market biotech products. In 2023, his total compensation was around $5.48 million, which included a significant amount in stock options. Interestingly, he's been active in insider trading throughout his time at Altimmune, with notable sales reaching over $7 million during some months. This suggests he has confidence in the company's future. Garg's focus remains on advancing Altimmune's biotechnology candidate pipeline, and he is known for successfully forming strategic partnerships to drive the company's growth.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Altimmune CEOs

A

Vipin K. Garg

CEO of Altimmune

Education

Ph.D. in Biochemistry from the University of Adelaide

Field of Expertise

Healthcare & Life Sciences - Biochemistry

Sector of Economy

Healthcare

Born

January 1, 1956 - 69 years ago

CEO of Altimmune for

6 years 7 months (Nov 2018 - Present)

Previous Experience

President and CEO of Neos Therapeutics, Inc.

Rivals

Competitors/colleagues of Vipin K. Garg

Holdings

See how much did Vipin K. Garg make over time.

Dr. Vipin K. Garg has a considerable stake in Altimmune. In 2023, he had impressive trading activity, selling shares amounting to millions during certain months, with peaks of over $7 million in one month alone. His holdings seem to have...

Dr. Vipin K. Garg has a considerable stake in Altimmune. In 2023, he had impressive trading activity, selling shares amounting to millions during certain months, with peaks of over $7 million in one month alone. His holdings seem to have fluctuated significantly since he became CEO. His wealth was significantly tied to Altimmune shares when he sold $3.79 million worth in January 2023 alone. This pattern shows he’s actively involved in managing his investments, periodically selling large amounts while still holding significant shares. This level of activity indicates that he is confident about the company’s direction and his influence on its success.

Mar 18, 2025

A

shares

ALT @ $5.61

Total Stock Sold

$702.00K

ALT

$702.00K

35,000 ALT shares

What if they kept their stock?

If Vipin K. Garg didn't sell their stock, today they would have:
Extra ALT35,000 shares worth $248.85K.
This is -64.55% and $453.15K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Vipin K. Garg.

ALT

$42.53K

ALT at $5.18/share

Jan 30, 2025

Received

ALT

$21.22K

ALT at $2.69/share

Jan 30, 2024

Received

ALT

$354.06

ALT at $2.81/share

Jul 31, 2023

Received

ALT

$19.78K

ALT at $10.21/share

Jan 31, 2023

Received

ALT

$400.32K

ALT at $20.02/share

Aug 30, 2022

Sale

ALT

$225.89K

ALT at $15.06/share

Aug 12, 2022

Sale

ALT

$18.91K

ALT at $6.86/share

Jan 31, 2022

Received

ALT

$12.81K

ALT at $12.14/share

Jan 31, 2021

Received

ALT

$17.04K

ALT at $1.46/share

Jul 31, 2020

Received

ALT

$16.48K

ALT at $1.46/share

Jan 31, 2020

Received

Compensation History

See how much did Vipin K. Garg make over time.

In 2023, Vipin K. Garg earned a total of around $5.48 million as CEO of Altimmune. His compensation package included a base salary of about $620,154, with no bonuses, likely reflecting a focus on long-term results. The bulk of his pay came from stock options and equity awards, aligning his interests with those of shareholders. The performance metrics used to assess his bonuses focused on advancing the candidate pipeline and forming strategic partnerships. This kind of structure is common in biotech, where executives are encouraged to drive growth while keeping the company's long-term vision in mind. His total compensation showcases how biotech CEOs often earn a large part of their money through stock performance rather than just a salary.

Year

2023

Total Compensation

$2.33M

Salary

$620.15K

Board Justification

The compensation philosophy is designed to attract, retain, and motivate executives by aligning their interests with those of stockholders through a combination of cash and equity-based incentives, with a focus on performance and long-term value creation.

Bonus

$0.00

Board Justification

For the year ended December 31, 2023, the annual performance-based cash bonuses were determined based on the achievement of corporate objectives set by the Board of Directors, with an achievement level of approximately 100% of the target annual performance-based cash bonuses for the Named Executive Officers.

Other

$334.95K

Board Justification

Other compensation includes contributions to the 401(k) plan, health savings account match, and commuting expenses.

Restricted Stock

$1.38M(1.38M RSU)

Board Justification

The stock awards that vested in 2023 were granted under the Altimmune, Inc. 2017 Omnibus Incentive Plan, aligning the interests of the Named Executive Officers with those of stockholders.

Performance Metrics

The performance metrics for determining the compensation in 2023 included advancing the candidate pipeline, completing strategic assessments, forming strategic partnerships, and managing operations effectively.

Other Altimmune CEOs

Here are other CEOs of Altimmune

William J. Enright

Ex-CEO of Altimmune

June 2008 - February 2019